{
“@context”: “https://schema.org”,
“@type”: “Article”,
“mainEntityOfPage”: {
“@type”: “WebPage”,
“@id”: “https://www.clinicalstudies.in/sop-for-study-closeout-site-and-sponsor”
},
“headline”: “SOP for Study Closeout (Site and Sponsor)”,
“description”: “This SOP defines the standardized process for study closeout activities at both site and sponsor levels, including TMF/ISF reconciliation, IP accountability, subject follow-up, regulatory notifications, and archiving, ensuring compliance with FDA, EMA, CDSCO, WHO, and ICH GCP requirements.”,
“author”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”
},
“publisher”: {
“@type”: “Organization”,
“name”: “ClinicalStudies.in”,
“logo”: {
“@type”: “ImageObject”,
“url”: “https://www.clinicalstudies.in/logo.png”
}
},
“datePublished”: “2025-08-26”,
“dateModified”: “2025-08-26”
}
Published on 21/12/2025
Standard Operating Procedure for Study Closeout (Site and Sponsor)
| SOP No. | CR/OPS/101/2025 |
| Supersedes | NA |
| Page No. | 1 of 48 |
| Issue Date | 26/08/2025 |
| Effective Date | 01/09/2025 |
| Review Date | 01/09/2026 |
Purpose
The purpose of this SOP is to outline the procedures for clinical study closeout at both the site and sponsor levels. It ensures
Scope
This SOP applies to sponsors, CROs, investigators, site staff, QA, and vendors involved in clinical trial conduct. It covers all site-level and sponsor-level closeout activities for interventional and non-interventional studies across all therapeutic areas.
Responsibilities
- Sponsor: Oversees study-wide closeout activities, ensures TMF completeness, and regulatory submissions.
- Investigator: Completes ISF closeout, subject follow-up, and IP accountability.
- CRA/Monitor: Performs site closeout visits and ensures compliance with closeout checklist.
- QA: Audits TMF/ISF for completeness prior to closeout.
- Archivist: Archives study documents in compliance with retention timelines.
Accountability
The Sponsor’s Clinical Operations Head is accountable for ensuring study closeout procedures are completed. Investigators are accountable for site-level closeout activities. QA is accountable for verifying regulatory compliance.
Procedure
1. Site Closeout Preparation
1.1 Confirm completion of subject visits and follow-up activities.
1.2 Reconcile IP and document returns/destruction in IP Reconciliation Log.
1.3 Ensure all data queries are resolved prior to database lock.
2. Site Closeout Visit
2.1 CRA conducts site closeout visit using Closeout Checklist (Annexure-1).
2.2 Review ISF for completeness, ensure informed consent forms, source data, and essential documents are in place.
2.3 Document findings in Site Closeout Visit Report.
3. Sponsor-Level Closeout
3.1 Reconcile TMF and verify completeness using TMF Index.
3.2 Ensure regulatory submissions (e.g., final CSR, registry updates) are initiated.
3.3 Notify EC/IRB and regulators of study closure.
4. Archiving
4.1 Archive ISF and TMF in compliance with ICH GCP and regional regulations.
4.2 Maintain Archive Log (Annexure-2).
5. Subject Communication
5.1 Provide subjects with final study updates as per protocol.
5.2 Ensure ongoing safety follow-up for unresolved AEs.
6. Documentation
6.1 Maintain Closeout Documentation Log (Annexure-3).
6.2 Ensure all final closeout reports are signed by responsible parties.
Abbreviations
- SOP: Standard Operating Procedure
- CRA: Clinical Research Associate
- QA: Quality Assurance
- IP: Investigational Product
- TMF: Trial Master File
- ISF: Investigator Site File
- CSR: Clinical Study Report
- AE: Adverse Event
- EC/IRB: Ethics Committee/Institutional Review Board
Documents
- Site Closeout Checklist (Annexure-1)
- Archive Log (Annexure-2)
- Closeout Documentation Log (Annexure-3)
References
- ICH E6(R2/R3) – Clinical Study Closeout
- FDA – Study Termination and Closeout Guidance
- EMA – Study Closure and CSR Requirements
- CDSCO – Clinical Trial Closeout Rules
- WHO – Guidelines for Clinical Trial Closeout
Version: 1.0
Approval Section
| Prepared By | Ravi Kumar, Clinical Research Associate |
| Checked By | Sunita Reddy, QA Officer |
| Approved By | Dr. Anil Sharma, Head Clinical Operations |
Annexures
Annexure-1: Site Closeout Checklist
| Activity | Status | Remarks |
|---|---|---|
| All subject visits completed | Yes | Final subject follow-up done |
| IP accountability completed | Yes | Returned/destroyed |
Annexure-2: Archive Log
| Date | Document Type | Location | Archived By |
|---|---|---|---|
| 15/09/2025 | TMF | Central Archive | Archivist |
Annexure-3: Closeout Documentation Log
| Date | Document | Prepared By | Reviewed By | Status |
|---|---|---|---|---|
| 20/09/2025 | Site Closeout Report | CRA | QA Officer | Completed |
Revision History
| Revision Date | Revision No. | Revision Details | Reason for Revision | Approved By |
|---|---|---|---|---|
| 26/08/2025 | 00 | Initial version | New SOP creation | Head Clinical Operations |
For more SOPs visit: Pharma SOP